For Primary central nervous system lymphoma:
In non-AIDS cases, chemotherapy combined with XRT prolongs survival compared to XRT alone. 1).
Rituximab is available since 1997 for the treatment of refractory systemic B-cell non-Hodgkin lymphoma. Intrathecally may be more effective for CD33 + lymphomas.